Revista internacional de salud mental de emergencia y resiliencia humana

Abstracto

Carbohydrate Deficient Transferrin: How reliable is it as a Biomarker for Chronic Alcohol Consumption?

Hamad Al-Ghafri, Ahmed Yousif Ali, Abuelgasim El-Rasheed, Samya Al-Mamari

Alcohol use disorders are a major cause of a number of health, economic and social challenges for individuals, their families and health care systems worldwide. The inadequate and inaccurate assessment of long-term drinking demeanors is a significant and substantial hindrance to its diagnosis and management. Biomarkers for chronic alcohol consumption are now well established as reliable diagnostic aids but their sensitivity and specificity still need to improve. Therefore, there is a definitive need for the development of more sensitive and specific markers of alcohol abuse and addiction. Biological markers of alcoholism are divided into two cohorts: conventional and circumstantial indices. Lineal markers are detected in some biological fluids including blood and urine. The other matrices encompassing hair, saliva and sweat are not yet internationally accepted and approved, despite some studies seems to be promising for some. Among the conventional biomarkers which ate tested for alcohol misuse and abuse are ethanol, ethyl glucuronide and ethyl sulfate. The conventional biomarkers, directly detect the alcohol consumption, with variable degrees of sensitivity and reliability. The circumstantial markers including MCV, γ-GT, transaminase enzymes SGOT (Serum Glutamate Oxaloacetate Transaminase) & SGPT (Serum Glutamate Pyruvate Transaminase) and carbohydrate-deficient transferrin. These biological markers are affected by heavy alcohol consumption for long periods. Objective: Our prime objective of this article is to review the available literature on CDT (Carbohydrate Deficient Transferrin) as a biomarker for chronic alcohol consumption and its role in diagnosing and monitoring alcohol use disorders. We also aim to enrich and add to the scientific debate and knowledge about the manifest reliability of this biomarker.